Epstein–Barr virus‐associated lymphoproliferative disease in a patient with Shimke immuno‐osseous dysplasia

Documenti analoghi

• Ruxolitinib for preventing relapse of Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis
  di: Eri Okura, et al.
  Pubblicazione: (2025)
• Efficacy of Noninvasive Neurally Adjusted Ventilatory Assist (NIV‐NAVA) for Neonates With Transient Tachypnea of the Newborn: A Retrospective Analysis
  di: Takamasa Saito, et al.
  Pubblicazione: (2025)
• Risk‐Stratified Phase II Clinical Trial for Epstein–Barr Virus‐Associated Hemophagocytic Lymphohistiocytosis in Pediatric, Adolescent, and Young Adult Patients in Japan
  di: Kenichi Sakamoto, et al.
  Pubblicazione: (2025)
• Epstein–Barr virus‐associated post‐transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States
  di: Tetsuya Tajima, et al.
  Pubblicazione: (2024)
• Long‐Term Outcomes of Reduced‐Toxicity Conditioning Using 8‐Gray Total Body Irradiation, Fludarabine, and Cyclophosphamide in Children, Adolescents, and Young Adults With Hematological Malignancies
  di: Hirokazu Morokawa, et al.
  Pubblicazione: (2024)